IN2015DN01975A - - Google Patents
Info
- Publication number
- IN2015DN01975A IN2015DN01975A IN1975DEN2015A IN2015DN01975A IN 2015DN01975 A IN2015DN01975 A IN 2015DN01975A IN 1975DEN2015 A IN1975DEN2015 A IN 1975DEN2015A IN 2015DN01975 A IN2015DN01975 A IN 2015DN01975A
- Authority
- IN
- India
- Prior art keywords
- diabetes
- present
- treatment
- hypertension
- useful
- Prior art date
Links
- 229940127088 antihypertensive drug Drugs 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000001077 hypotensive effect Effects 0.000 abstract 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 abstract 1
- 230000007211 cardiovascular event Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 230000003907 kidney function Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261695016P | 2012-08-30 | 2012-08-30 | |
| PCT/JP2013/073300 WO2014034842A1 (ja) | 2012-08-30 | 2013-08-30 | Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01975A true IN2015DN01975A (enExample) | 2015-08-14 |
Family
ID=50183647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1975DEN2015 IN2015DN01975A (enExample) | 2012-08-30 | 2013-08-30 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9320727B2 (enExample) |
| EP (1) | EP2891499A4 (enExample) |
| JP (2) | JP6198013B2 (enExample) |
| KR (1) | KR20150046125A (enExample) |
| CN (1) | CN104780942A (enExample) |
| AU (1) | AU2013309904A1 (enExample) |
| BR (1) | BR112015004012A2 (enExample) |
| CA (1) | CA2883118A1 (enExample) |
| HK (1) | HK1208621A1 (enExample) |
| IN (1) | IN2015DN01975A (enExample) |
| MX (1) | MX2015002572A (enExample) |
| PH (1) | PH12015500434B1 (enExample) |
| RU (1) | RU2015110979A (enExample) |
| SG (1) | SG11201501510SA (enExample) |
| TW (1) | TW201414472A (enExample) |
| WO (1) | WO2014034842A1 (enExample) |
| ZA (1) | ZA201502009B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101943382B1 (ko) * | 2017-09-19 | 2019-01-29 | 오토텔릭바이오 주식회사 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
| CN109806397A (zh) * | 2017-11-20 | 2019-05-28 | 江苏恒瑞医药股份有限公司 | Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途 |
| KR102131359B1 (ko) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
| JP7659783B2 (ja) | 2019-09-13 | 2025-04-10 | 国立大学法人富山大学 | 急性心不全における体液貯留改善薬 |
| JP2023523596A (ja) * | 2020-04-22 | 2023-06-06 | バイエル アクチェンゲゼルシャフト | 心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ |
| CN116490178A (zh) * | 2020-08-17 | 2023-07-25 | 北京睿创康泰医药研究院有限公司 | Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途 |
| WO2022176981A1 (ja) * | 2021-02-19 | 2022-08-25 | 大正製薬株式会社 | 経口フィルム製剤 |
| US20250000849A1 (en) * | 2021-10-27 | 2025-01-02 | Meditake Co., Ltd. | Composite composition containing angiotensin receptor blocker and sglt2 inhibitor |
| KR20240099023A (ko) * | 2022-12-20 | 2024-06-28 | 주식회사 티에치팜 | 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 심혈관 질환 예방 또는 치료용 약학적 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| DE102004048388A1 (de) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| JP5194588B2 (ja) | 2006-07-06 | 2013-05-08 | 大正製薬株式会社 | １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤 |
| TW200904405A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| EP2147008A2 (en) * | 2007-05-18 | 2010-01-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
| WO2010048358A2 (en) * | 2008-10-22 | 2010-04-29 | Auspex Pharmaceutical, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
| CN105434430A (zh) * | 2009-04-16 | 2016-03-30 | 大正制药株式会社 | 药物组合物 |
| CN106075451A (zh) | 2009-05-27 | 2016-11-09 | 阿斯利康(瑞典)有限公司 | 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法 |
-
2013
- 2013-08-30 TW TW102131295A patent/TW201414472A/zh unknown
- 2013-08-30 MX MX2015002572A patent/MX2015002572A/es unknown
- 2013-08-30 WO PCT/JP2013/073300 patent/WO2014034842A1/ja not_active Ceased
- 2013-08-30 IN IN1975DEN2015 patent/IN2015DN01975A/en unknown
- 2013-08-30 BR BR112015004012A patent/BR112015004012A2/pt not_active IP Right Cessation
- 2013-08-30 CN CN201380045221.4A patent/CN104780942A/zh active Pending
- 2013-08-30 AU AU2013309904A patent/AU2013309904A1/en not_active Abandoned
- 2013-08-30 EP EP13832429.8A patent/EP2891499A4/en not_active Withdrawn
- 2013-08-30 CA CA2883118A patent/CA2883118A1/en not_active Abandoned
- 2013-08-30 RU RU2015110979A patent/RU2015110979A/ru not_active Application Discontinuation
- 2013-08-30 US US14/424,096 patent/US9320727B2/en not_active Expired - Fee Related
- 2013-08-30 SG SG11201501510SA patent/SG11201501510SA/en unknown
- 2013-08-30 HK HK15109273.2A patent/HK1208621A1/xx unknown
- 2013-08-30 KR KR20157006606A patent/KR20150046125A/ko not_active Withdrawn
- 2013-08-30 JP JP2014533107A patent/JP6198013B2/ja active Active
-
2015
- 2015-02-27 PH PH12015500434A patent/PH12015500434B1/en unknown
- 2015-03-24 ZA ZA2015/02009A patent/ZA201502009B/en unknown
-
2017
- 2017-05-31 JP JP2017107661A patent/JP6358515B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017186353A (ja) | 2017-10-12 |
| US9320727B2 (en) | 2016-04-26 |
| PH12015500434B1 (en) | 2022-04-22 |
| JP6358515B2 (ja) | 2018-07-18 |
| SG11201501510SA (en) | 2015-04-29 |
| JPWO2014034842A1 (ja) | 2016-08-08 |
| TW201414472A (zh) | 2014-04-16 |
| BR112015004012A2 (pt) | 2017-07-04 |
| RU2015110979A (ru) | 2016-10-20 |
| KR20150046125A (ko) | 2015-04-29 |
| MX2015002572A (es) | 2015-06-05 |
| PH12015500434A1 (en) | 2015-04-20 |
| HK1208621A1 (en) | 2016-03-11 |
| US20150320721A1 (en) | 2015-11-12 |
| AU2013309904A1 (en) | 2015-03-19 |
| WO2014034842A1 (ja) | 2014-03-06 |
| EP2891499A4 (en) | 2016-02-24 |
| CA2883118A1 (en) | 2014-03-06 |
| EP2891499A1 (en) | 2015-07-08 |
| ZA201502009B (en) | 2016-07-27 |
| JP6198013B2 (ja) | 2017-09-20 |
| CN104780942A (zh) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN01975A (enExample) | ||
| PH12020500352A1 (en) | Therapeutic uses of empagliflozin | |
| GEP201706719B (en) | Pirfenidone treatment for patients with atypical liver function | |
| PH12015500407A1 (en) | Methods of treating hypertriglyceridemia | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12015502136A1 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| MX2020013740A (es) | Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular. | |
| PH12013501790B1 (en) | Use of dpp iv inhibitors | |
| PH12013500808A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| IN2015DN03219A (enExample) | ||
| BR112012022552A2 (pt) | uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas | |
| WO2009068659A3 (en) | Novel disease treatment by predicting drug association | |
| IN2014CN03123A (enExample) | ||
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| PH12015500653A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| GB2496795A (en) | A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system | |
| WO2013192610A3 (en) | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | |
| MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| MX2013011096A (es) | Metodos de tratamiento dirigido a degeneracion lobular frontotemporal. | |
| HK1200731A1 (en) | Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy | |
| MX358072B (es) | Composiciones tópicas que comprenden diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que involucran un aumento del dolor. | |
| PH12014500340A1 (en) | Pharmaceutical composition comprising a drug containing at least one toxicophore function and n-acetyl-l-cysteine | |
| MX2011005899A (es) | Composicion farmacéutica con antihistamínico no sedante y combinaciones. |